The new discoveries and inventions, including genes involved, therapeutic compounds, and treatment procedures, will provide grounds for significant improvement in SEGA treatment, as once the discovery of the TSC1 and TSC2 genes, rapamycin, and acting components of the mTOR pathway led to the creation of new treatment opportunities for patients with tuberous sclerosis. This evidence concerns the gene TSC2 and tuberous sclerosis.